Squarepoint
IONS icon

Squarepoint’s Ionis Pharmaceuticals IONS Stock Holding History

Squarepoint’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,500
Closed -$277K – 4598
2025
Q4 		$277K Sell
3,500
-18,500
-84% -$1.39M ﹤0.01% 3662
2025
Q3 		$1.44M Buy
+22,000
New +$1.07M ﹤0.01% 2375
2025
Q1 		– Sell
-6,000
Closed -$210K – 4990
2024
Q4 		$210K Buy
+6,000
New +$224K ﹤0.01% 4440

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's IONS Position: Q1 2026 in Review

Squarepoint increased its Ionis Pharmaceuticals (IONS) stake by 59% in Q1 2026, buying an estimated $20.4M and bringing the position to 695,276 shares worth $52.2M. The position accounts for 0.06% of the portfolio, ranked #331.

Squarepoint first reported a position in IONS in Q2 2015 and has held it in 38 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Squarepoint held 695,276 shares of Ionis Pharmaceuticals worth $52.2M as of Q1 2026.
  • Squarepoint bought 258,997 Ionis Pharmaceuticals shares in Q1 2026, an estimated $20.4M.
  • Ionis Pharmaceuticals made up 0.06% of Squarepoint's portfolio in Q1 2026, its #331 holding.
  • Squarepoint first reported a position in Ionis Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.